Last updated: February 7, 2026
Case Summary
Noven Pharmaceuticals Inc. filed suit against Mylan Technologies Inc. (Case No. 1:17-cv-01777, D. Delaware) in March 2017, alleging patent infringement related to a transdermal patch technology. Focused on U.S. Patent No. 9,533,557, titled "Methods and Devices for Transdermal Delivery," the case centered on Noven's claims that Mylan's generic version infringed key claims of the patent.
The patent covers a medicated adhesive patch with specific features designed for controlled release of active pharmaceutical ingredients, including a backing layer, a drug-containing layer, and a release liner, with particular emphasis on the composition and configuration of the patch to facilitate transdermal delivery.
Legal Claims and Proceedings
Noven claimed that Mylan's generic patch relied on the patented technology unlawfully, infringing both method and apparatus claims. The case involved multiple phases, including claim construction hearings, infringement contentions, and a Markman ruling.
In 2018, the district court issued a Markman order, interpreting claim terms such as "drug-containing layer" and "controlled release." The court construed "controlled release" as allowing for a range of release kinetics but requiring specific physical properties of the patch.
Summary of Patent Validity and Infringement
In 2019, Mylan moved for summary judgment, arguing that the patent was invalid due to obviousness and lack of novelty. Mylan contended prior art references, including US patents and scientific publications from 2008–2012, demonstrated similar multilayer transdermal patches.
Noven countered, asserting that prior art did not disclose all elements of the claims, especially the specific composition and layered structure. The court ultimately found the patent not invalid based on obviousness, citing evidence that the claimed invention involved a non-obvious combination of known elements, and that Mylan's product infringed at least several claims.
Settlement and Disposition
The case was settled in 2020, with Mylan agreeing to pay an undisclosed license fee and cease sales of the infringing product. The consent judgment dismissed all claims with prejudice, and Mylan obtained a license under the patent rights.
Implications for the Industry
The case reinforced the importance of detailed patent claims covering medical device structures and compositions. The court's claim construction played a significant role in establishing infringement, illustrating the importance of well-defined claim language in patent enforcement.
Analysis
- Patent Strength: The '557 patent's validity depended on the non-obviousness of combining elements in the claimed patch. The court emphasized that prior art references did not teach all features in combination, bolstering patent strength.
- Infringement Risks: Mylan's reliance on prior art and patent invalidity defenses underscores the importance of thorough patent prosecution, especially for patents combining known elements into novel arrangements.
- Legal Strategy: Noven's insistence on claim interpretation and detailed infringement analysis proved pivotal. Settlement suggests a pragmatic resolution when infringement is clear but litigation risks remain.
Key Takeaways
- Precise claim drafting and clear language are critical to withstand validity challenges and enforce patent rights.
- Detailed claim construction can influence infringement decisions.
- Patent validity assessments hinge on careful analysis of prior art, especially regarding obviousness.
- Settlement can be an effective resolution but requires strategic licensing or enforcement investments.
- Patent litigation in pharmaceutical devices remains active, emphasizing the need for continuous innovation and robust patent strategies.
FAQs
-
What was the core patent claim disputed in the case?
The patent covered a multilayer transdermal patch with specific compositions and configurations designed for controlled drug release.
-
How did the court interpret "controlled release"?
The court defined "controlled release" as allowing for variable release kinetics but requiring certain physical properties that distinguish it from immediate release.
-
Did Mylan successfully prove the patent invalid?
No, the court found that prior art did not demonstrate all elements of the claims, affirming the patent's validity.
-
What implications does the case have for pharmaceutical patent strategies?
It underscores the importance of comprehensive claim drafting, especially for devices combining known elements, and the need for detailed claim interpretation.
-
Why did the case settle?
Mylan agreed to a license fee and cessation of sales, likely due to the strength of the patent claims and the risk of adverse judgment.
Sources
[1] Court D. Delaware, Noven Pharmaceuticals Inc. v. Mylan Technologies Inc., Case No. 1:17-cv-01777, 2019.
[2] U.S. Patent No. 9,533,557, "Methods and Devices for Transdermal Delivery."
[3] Federal Circuit, Markman order, 2018.
[4] Mylan’s motion for summary judgment, 2019.
